Regeneron Pharmaceuticals, Inc.
Corporate Headquarters
777 Old Saw Mill River Road
Tarrytown
New York
10591
United States
Tel: 914-847-7000
Website: https://www.regeneron.com/
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
Stock Symbol: REGN
Stock Exchange: NASDAQ
Every day, we use our homegrown technologies to discover, develop, research and deliver new medicines that help people with serious diseases. Watch to see what drives us.
Learn more about how our team produces the highest-quality treatments for patients at https://www.regeneron.com/.
1270 articles with Regeneron Pharmaceuticals, Inc.
-
Regeneron’s oncology strategy is centered around improving checkpoint inhibitor treatments with combination therapies, according to a pipeline overview presented Monday morning.
-
Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM
9/12/2022
Regeneron Pharmaceuticals, Inc. announced positive clinical data for an investigational regimen of PD-1 inhibitor Libtayo® as neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma.
-
Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors
9/12/2022
Regeneron Pharmaceuticals, Inc. announced the presentation of positive data from multiple expansion cohorts of an initial Phase 1 trial for an investigational combination of LAG-3 inhibitor fianlimab and PD-1 inhibitor Libtayo® in advanced melanoma.
-
The week has seen a series of significant updates from BioVie, Regeneron, Relay Therapeutics, Oxford University, Vistagen and Palatin.
-
Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors
9/10/2022
Regeneron Pharmaceuticals, Inc. announced positive early data for two novel and investigational bispecific antibodies – ubamatamab in recurrent ovarian cancer and REGN5093 in MET-altered advanced non-small cell lung cancer.
-
Regeneron Announces Investor Call and Webcast at ESMO 2022
9/9/2022
Regeneron Pharmaceuticals, Inc. will host a conference call and simultaneous webcast to share updates on the company's oncology portfolio in conjunction with the European Society for Medical Oncology Annual Congress on Monday, September 12, 2022.
-
Sanofi and Regeneron presented results from the Phase III PRIME trial that showed Dupixent strongly improves itching and skin lesions in adult patients with prurigo nodularis.
-
Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis
9/8/2022
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented detailed positive results from the second of two Phase 3 trials (PRIME) evaluating Dupixent® (dupilumab) in adults with uncontrolled prurigo nodularis in a late-breaking session at the European Academy of Dermatology and Venereology (EADV) 2022 Congress.
-
Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals
9/8/2022
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD).
-
Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma
9/5/2022
Regeneron Pharmaceuticals, Inc. and Sanofi announced results from a Phase 3 open-label extension trial demonstrating the efficacy and safety profile of Dupixent® as a maintenance therapy when added to other asthma medications was consistent for up to two years in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma with evidence of type 2 inflammation.
-
Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma
9/5/2022
Results from a Phase 3 open-label extension trial demonstrated the efficacy and safety profile of Dupixent® as a maintenance therapy when added to other asthma medications was consistent for up to two years in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma with evidence of type 2 inflammation.
-
ESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers
9/4/2022
Regeneron Pharmaceuticals, Inc. announced that new and updated data across its oncology pipeline will be presented at the European Society for Medical Oncology Congress 2022 from September 9 to 13 in Paris.
-
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
8/29/2022
Alnylam Pharmaceuticals, Inc. today announced positive results from a Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway, in development in collaboration with Regeneron Pharmaceuticals for the treatment of adult patients with immunoglobulin A nephropathy (IgAN).
-
Finding a job right out of college can seem like a daunting task. To help, BioSpace has compiled a list of the top companies hiring new grads for entry-level roles.
-
Regeneron Announces Investor Conference Presentations in September 2022
8/25/2022
Regeneron Pharmaceuticals, Inc. will webcast management participation as follows.
-
Researchers found promising connections between the Neuregulin 4 (NRG4) endocrine factor protein and the suppression of specific liver diseases, including NASH.
-
Biogen expects to lay off a potential 1,000 staffers in an effort to cut about $1 billion in costs, according to The Boston Globe, while 10x Genomics and Talis Biomedical also cut staff.
-
Regeneron and partner Alnylam have developed a siRNA therapeutic candidate targeting CIDEB gene that the companies anticipate will enter the clinic within the next year.
-
Regeneron Reports Second Quarter 2022 Financial and Operating Results
8/3/2022
Regeneron Pharmaceuticals, Inc. announced financial results for the second quarter of 2022 and provided a business update.
-
Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
8/3/2022
Regeneron Pharmaceuticals, Inc. announced encouraging initial data from an ongoing Phase 1/2 trial investigating REGN5678, a novel PSMAxCD28 costimulatory bispecific antibody, in combination with the company's PD-1 inhibitor Libtayo® in advanced metastatic castration-resistant prostate cancer.